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The leukemia-associated RUNX1/ETO oncoprotein confers a mutator phenotype Leukemia (2016) 30, 250-253; doi:10.1038/leu.2015.133 t(8;21) is a frequent chromosomal translocation in acute myeloid leukemia (AML) and is also reported in lymphoid and biphenotypic acute leukemia.
1,2 t(8;21) fuses the RUNX1 gene (AML1) on chromosome 21 to the ETO gene (RUNX1T1) on chromosome 8, encoding the RUNX1/ETO chimeric transcription factor that represses expression of RUNX1 target genes, promoting selfrenewal and blocking myeloid differentiation. [3] [4] [5] [6] t(8;21) is insufficient for leukemogenesis and additional co-operating mutations are required for transformation, 7 including point mutations that activate and/or over express c-KIT. 8 The mechanisms driving the acquisition of co-operating mutations remain unclear, although there is evidence that initiating lesions such as RUNX1/ETO may promote mutagenesis. 9, 10 For example, ectopic expression of RUNX1/ETO downregulates several DNA-repair proteins (BRCA2, OGG1 and ATM) and increases the level of phosphorylated TP53 and γH2AX, indicating elevated DNA damage and a possible pro-mutagenic phenotype. 10, 11 To test whether expression of RUNX1/ETO is sufficient to increase genomic instability and mutagenesis, we expressed RUNX1/ETO in the non-transformed TK6 lymphoblastoid cell line and measured the acquisition of mutations at the PIGA reporter gene. Cells were transduced with lentivirus carrying either enhanced green fluorescent protein (EGFP) and the RUNX1/ETO fusion or EGFP alone (vector control) (Supplementary Figure 1A ; Supplementary Methods) and clones expressing both RUNX1/ETO mRNA and protein were generated (Supplementary Figures 1B and C) . For the purposes of measuring RUNX1/ETO-induced mutagenesis, we analysed independent cell clones expressing at least 40% of the fusion transcript found in the Kasumi-1 and SKNO-1 t(8;21)-positive cell lines (Supplementary Figure 1B) . Monitoring of RUNX1/ETO-positive clones revealed that expression of the fusion was stable over long culture periods (412 weeks). Independent vector control clones that expressed equivalent levels of EGFP to RUNX1/ETO-positive cells were used as fusionprotein negative controls (Supplementary Figure 1D) .
PIGA encodes a protein essential for production of the glycosylphosphatidylinositol anchor, mediating anchoring of proteins including CD55 and CD59 to the cell membrane. 12 Somatic mutations of PIGA are growth neutral and can be determined using flow cytometry analysis measuring CD55 and CD59 expression (Supplementary Figure 2 ; Supplementary Methods). Using this reporter gene system we determined the mutation frequency (Mf) in several independent RUNX1/ETOexpressing and vector control clones after continuous culture for 8-10 weeks after initial cloning. All clones had a majority population that was positive for CD55 and CD59, confirming that the founding cell was PIGA wild-type (WT). The mean PIGA Mf in RUNX1/ETO clones (7.50 × 10 − 4 ) was five times higher than in vector control clones (1.45 × 10 − 4 ) ( Figure 1a , Supplementary Figure 3A ) (P = 0.032), with the exception of a single clone that had low expression of the fusion transcript (equivalent to 40% of that in Kasumi-1) (Supplementary Figures 1B and 3A) .
The frequency of cells with a mutation (Mf) at a specific gene is determined by the mutation rate per cell division for that gene (μ) and the number of cell divisions (d). Expression of the RUNX1/ETO fusion had a modest but nonsignificant negative effect on cell proliferation (Figure 1b Table 1 ). These data demonstrate that expression of the RUNX1/ETO fusion oncoprotein confers a mutator phenotype when the transcript is at levels equivalent to at least 60% of that in t(8;21)-positive cell lines.
We next investigated whether RUNX1/ETO transduced cells were particularly sensitive to mutagenesis following exposure to genotoxic anticancer therapies. Fusion protein-positive and vector control clones were exposed to sub-cytotoxic doses of either doxorubicin (100 nM for 4 h) or ionising radiation (3 Gy), and Mf was measured 2 weeks after treatment. The frequency of mutations attributable to doxorubicin or radiation (treatment- We next investigated whether EGFP expression differed in treatment-induced PIGA mutant cells compared with non-mutant cells derived from the same RUNX1/ETO clonal population. The EGFP GMoF of PIGA mutant cells was significantly higher than in non-mutant cells following treatment with doxorubicin (P = 0.03) or ionising radiation (P = 0.02) (Figures 2b and c,  Supplementary Figure 6 ). In contrast, the EGFP GMoF was not significantly different between PIGA mutant and WT cells derived from vector control populations following treatment (Figures 2b and c) .
These data demonstrate that high levels of RUNX1/ETO sensitise cells to acquisition of mutations following treatment with DNA damage-inducing agents, suggesting that fusion-protein-expressing cells may be compromised in DNA repair. This result is consistent with previously published reports implicating compromised OGG1 DNA glycosylase activity in t(8;21) AML. 11, 13 OGG1 functions in base excision repair and initiates repair of oxidised lesions, including 8-hydroxy-2′-deoxyguanosine. We therefore investigated OGG1 expression in 18 independent RUNX1/ETO cell clones and observed that transcript levels were inversely proportional to the expression of the fusion gene (Supplementary Figure 7A) . Likewise, OGG1 protein levels were consistently lower in RUNX1/ETO-positive clones compared with vector control clones (Supplementary Figure 7B) . We next performed siRNA-mediated depletion of RUNX1/ETO in Kasumi-1, as previously described. 5 Two serial electroporations with either RUNX1/ETO or control scrambled siRNA were carried out and OGG1 transcript and protein levels were assessed 72 h after each electroporation. RUNX1/ETO depletion increased OGG1 transcript levels by fourfold and sixfold on days 3 and 6, respectively (Supplementary Figure 7C) with a concomitant increase in OGG1 protein (Supplementary Figures 7C and D) . To confirm OGG1 as a RUNX1/ETO target gene we performed ChIP and RNA sequencing after siRNA-mediated RUNX1/ETO depletion. A RUNX1/ETO CHiPseq peak was observed at the OGG1 promoter in control-transfected Kasumi-1 cells, which was lost following siRNA-mediated fusion protein depletion (Supplementary Figure 7E) and was co-localised within a DNaseI hypersensitivity site, as previously reported. 6 We also confirmed the increase in OGG1 expression after RUNX1/ ETO depletion by RNAseq (Supplementary Figure 7E) . Taken together, these data confirm that the RUNX1/ETO fusion protein binds the OGG1 promoter and negatively regulates transcription, suggesting a plausible mechanism by which this common fusion oncoprotein drives mutagenesis. In order to investigate this further, we interrogated whole-genome and exome sequencing data from The Cancer Genome Atlas Project.
14 Data were available from 193 AML cases, which included information on 21 386 somatic base substitution mutations, including G4T transversions, the predominant mutation that arises following translesion synthesis of 8-hydroxy-2′-deoxyguanosine and which accumulates following knockdown of OGG1 in experimental systems. 15 When stratified by cytogenetic subgroup, 16.13% of all mutations in t(8;21) AML were G4T transversions (16.13%, n = 7 cases, Supplementary Table 2), which was higher than any other cytogenetic subgroup and all other AML cases combined (12.14%, n = 186 cases), although this did not reach statistical significance (P = 0.31, Yates chi-square). These data are consistent with loss of OGG1 contributing to the mutator phenotype in RUNX1/ETO cells by predisposing to G:C4T:A transversions.
By using mutation assays using two independent assays, we have shown that RUNX1/ETO predisposes to the acquisition of Histogram shows the mean from five RUNX1/ETO clones and four vector control clones. Error bars represent the standard deviation. RUNX1/ ETO PIGA mutants had a significantly higher EGFP fluorescence than PIGA WT RUNX1/ETO cells from the same population after treatment with doxorubicin or radiation, whereas no significant difference was observed between vector control PIGA mutant and WT cells (P = 0.01 for doxorubicin and P = 0.01 for radiation; one tailed unpaired Student's t-test using fold change in fluorescence between PIGA WT and mutant cells and comparing RUNX1/ETO clones and vector control clones). Chronic myeloid leukemia (CML) is characterized by the BCR/ABL1 fusion gene formed by a t(9;22) chromosomal translocation. The t(9;22) is thought to arise in a hematopoietic stem cell creating a hierarchically arranged leukemia with a subset of cells in the CD34 + CD38 low fraction comprising the primitive leukemia initiating cells, also termed leukemic stem cells. 1, 2 The treatment of CML was greatly improved with the introduction of tyrosine kinase inhibitors more than a decade ago, but not all patients respond optimally to the initial treatment and even after obtaining a deep molecular remission, discontinuation of treatment is often followed by a relapse. [3] [4] [5] The leukemic stem cell (LSC) burden of CML patients at diagnosis could potentially provide an important disease variable Accepted article preview online 12 June 2015; advance online publication, 30 June 2015
